Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,671 shares of the medical research company’s stock after buying an additional 78 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in IQVIA were worth $846,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Knott David M Jr acquired a new position in IQVIA during the 2nd quarter worth about $26,000. Clear Investment Research LLC acquired a new position in IQVIA during the 3rd quarter worth about $27,000. Trust Co. of Vermont acquired a new position in IQVIA during the 3rd quarter worth about $45,000. Eisler Capital UK Ltd. acquired a new position in shares of IQVIA in the 3rd quarter valued at about $54,000. Finally, Guardian Wealth Advisors LLC acquired a new position in shares of IQVIA in the 3rd quarter valued at about $57,000. 86.20% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the company. SVB Leerink reissued an “outperform” rating on shares of IQVIA in a research note on Friday, January 27th. Credit Suisse Group reissued an “outperform” rating and issued a $265.00 price objective on shares of IQVIA in a research note on Monday, February 13th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, February 18th. Citigroup downgraded IQVIA from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $275.00 to $245.00 in a research note on Thursday, November 17th. Finally, Cowen assumed coverage on IQVIA in a research note on Tuesday, December 6th. They issued an “outperform” rating and a $251.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $256.27.
IQVIA Stock Performance
IQVIA (NYSE:IQV – Get Rating) last issued its quarterly earnings data on Friday, February 10th. The medical research company reported $2.78 EPS for the quarter, topping analysts’ consensus estimates of $2.76 by $0.02. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.71 billion. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.42 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 9.51 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the sale, the insider now directly owns 17,053 shares of the company’s stock, valued at approximately $3,922,190. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the completion of the transaction, the insider now directly owns 1,973 shares of the company’s stock, valued at $445,128.53. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now directly owns 17,053 shares of the company’s stock, valued at $3,922,190. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.
IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.